PL2114405T3 - Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem - Google Patents

Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem

Info

Publication number
PL2114405T3
PL2114405T3 PL07857734T PL07857734T PL2114405T3 PL 2114405 T3 PL2114405 T3 PL 2114405T3 PL 07857734 T PL07857734 T PL 07857734T PL 07857734 T PL07857734 T PL 07857734T PL 2114405 T3 PL2114405 T3 PL 2114405T3
Authority
PL
Poland
Prior art keywords
methanone
piperazin
methanesulfonyl
trifluoro
pyridin
Prior art date
Application number
PL07857734T
Other languages
English (en)
Polish (pl)
Inventor
André Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E Rohrer
Urs Schwitter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2114405(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2114405T3 publication Critical patent/PL2114405T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL07857734T 2006-12-28 2007-12-18 Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem PL2114405T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
EP07857734.3A EP2114405B1 (en) 2006-12-28 2007-12-18 methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (1)

Publication Number Publication Date
PL2114405T3 true PL2114405T3 (pl) 2015-08-31

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07857734T PL2114405T3 (pl) 2006-12-28 2007-12-18 Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem

Country Status (33)

Country Link
US (5) US20080214561A1 (enExample)
EP (1) EP2114405B1 (enExample)
JP (1) JP4799666B2 (enExample)
KR (1) KR101130146B1 (enExample)
CN (1) CN101573114A (enExample)
AR (1) AR064545A1 (enExample)
AU (1) AU2007341356B2 (enExample)
BR (1) BRPI0720829B8 (enExample)
CA (1) CA2673667A1 (enExample)
CL (1) CL2007003830A1 (enExample)
CO (1) CO6190613A2 (enExample)
CR (1) CR10846A (enExample)
CY (1) CY1116350T1 (enExample)
DK (1) DK2114405T3 (enExample)
EC (1) ECSP099471A (enExample)
ES (1) ES2535040T3 (enExample)
HR (1) HRP20150573T1 (enExample)
HU (1) HUE025032T2 (enExample)
MA (1) MA31029B1 (enExample)
MX (1) MX2009006859A (enExample)
MY (1) MY188367A (enExample)
NO (1) NO342150B1 (enExample)
NZ (1) NZ577502A (enExample)
PE (1) PE20081556A1 (enExample)
PL (1) PL2114405T3 (enExample)
PT (1) PT2114405E (enExample)
RS (1) RS53910B1 (enExample)
RU (1) RU2463295C2 (enExample)
SI (1) SI2114405T1 (enExample)
TW (1) TWI388552B (enExample)
UA (1) UA100232C2 (enExample)
WO (1) WO2008080821A1 (enExample)
ZA (1) ZA200904423B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150573T1 (xx) 2006-12-28 2015-07-03 F. Hoffmann - La Roche Ag KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA
WO2010099323A1 (en) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
BR112014028872A2 (pt) * 2012-05-25 2017-06-27 Basf Se forma b cristalina, processo para a produção das formas b e ab, mistura da forma b cristalina, agente de proteção, uso da forma b cristalina e método para o combate do crescimento indesejado dos vegetais
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
CN115315298B (zh) * 2020-07-13 2023-09-15 日本碍子株式会社 精制方法
WO2022241274A1 (en) * 2021-05-14 2022-11-17 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
US20240390362A1 (en) * 2021-05-27 2024-11-28 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2004263306B2 (en) * 2003-08-11 2010-04-22 F. Hoffmann-La Roche Ag Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors
HRP20150573T1 (xx) 2006-12-28 2015-07-03 F. Hoffmann - La Roche Ag KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA

Also Published As

Publication number Publication date
US20080214561A1 (en) 2008-09-04
US8039473B2 (en) 2011-10-18
US20110295007A1 (en) 2011-12-01
US20100311971A1 (en) 2010-12-09
TW200833677A (en) 2008-08-16
NO342150B1 (no) 2018-04-03
TWI388552B (zh) 2013-03-11
SI2114405T1 (sl) 2015-06-30
EP2114405A1 (en) 2009-11-11
RS53910B1 (sr) 2015-08-31
MY188367A (en) 2021-12-06
KR20090094166A (ko) 2009-09-03
RU2009124113A (ru) 2011-02-10
ZA200904423B (en) 2010-05-26
KR101130146B1 (ko) 2012-03-28
PE20081556A1 (es) 2008-11-28
MX2009006859A (es) 2009-07-03
CY1116350T1 (el) 2017-03-15
EP2114405B1 (en) 2015-03-11
ES2535040T3 (es) 2015-05-04
CR10846A (es) 2009-08-12
CL2007003830A1 (es) 2008-07-11
HUE025032T2 (en) 2016-02-29
DK2114405T3 (en) 2015-04-07
UA100232C2 (uk) 2012-12-10
US20120309969A1 (en) 2012-12-06
BRPI0720829A2 (pt) 2014-02-25
MA31029B1 (fr) 2009-12-01
JP4799666B2 (ja) 2011-10-26
NZ577502A (en) 2012-02-24
WO2008080821A1 (en) 2008-07-10
AU2007341356B2 (en) 2013-08-29
PT2114405E (pt) 2015-06-02
RU2463295C2 (ru) 2012-10-10
US20130197225A1 (en) 2013-08-01
AU2007341356A1 (en) 2008-07-10
CN101573114A (zh) 2009-11-04
ECSP099471A (es) 2009-07-31
CO6190613A2 (es) 2010-08-19
HRP20150573T1 (xx) 2015-07-03
NO20092358L (no) 2009-06-22
JP2010514725A (ja) 2010-05-06
CA2673667A1 (en) 2008-07-10
BRPI0720829B8 (pt) 2021-05-25
AR064545A1 (es) 2009-04-08
BRPI0720829B1 (pt) 2020-04-07

Similar Documents

Publication Publication Date Title
PL2114405T3 (pl) Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
IL195511A0 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]
ZA200804198B (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
IL214178A0 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine
IL191729A0 (en) Assessment of electrode coupling for tissue ablation
WO2009043747A3 (en) N-heterocyclic biaryl carboxamides as ccr receptor antagonists
ZA200901270B (en) Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-D]-pyridimin-7-ones
WO2008038251A3 (en) 3-aza-bicyclo[3.1.0]hexane derivatives
LT2225230T (lt) 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzoinės rūgšties kietos formos
EP1854318A4 (en) DYNAMIC IDENTITY ASSOCIATION IN A WIRELESS NETWORK
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
UA95788C2 (en) Fused pyrrole derivatives
PT1874746E (pt) Derivados de 1-n-azacicloalquil-3-fenoxipropano úteis para a preparação de medicamentos psicotrópicos
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
SI2176229T1 (sl) Nove kristalne oblike 3-(difluormetil)-1-metil-n-(3',4',5'-trifluor(1,1'-bifenil)-2-il)-1h- pirazol-4-karboksamida
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
WO2009055289A3 (en) Therapeutic substituted lactams
IL195355A0 (en) Substituted pyrazinone derivatives for use as a medicine
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
HUP0500537A2 (en) Process for the preparation of rosuvastatin via new intermediates
ZA200801813B (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one
ZA200705514B (en) Preparation of pharmaceutical salts of piperazine compounds
WO2008110586A3 (en) New process for the preparation of levocetirizine and intermediates thereof